GYRE THERAPEUTICS, INC.

GYRE · Nasdaq · SIC 2834: Pharmaceutical Preparations
317
SEC Filings

Business Summary

. In this section, unless otherwise specified, references to we, our, us and our company refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) (Gyre Pharmaceuticals). Overview We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. We operate through our m...

Next Earnings

Q2 FY2026 — expected 2026-09-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionGYREdiscussed_in_filing Cybersecurity
topic_mentionGYREdiscussed_in_filing Cybersecurity
topic_mentionGYREdiscussed_in_filing Healthcare & Bio
topic_mentionGYREdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-132025-12-310001193125-26-106251EDGAR126K words
2025-03-172024-12-310000950170-25-040279EDGAR—
2024-03-272023-12-310000950170-24-037242EDGAR—
2023-03-302022-12-310001564590-23-004830EDGAR—
2022-03-312021-12-310001564590-22-012877EDGAR—
2021-03-042020-12-310001564590-21-010823EDGAR—
2020-02-202019-12-310001564590-20-005546EDGAR—
2019-03-082018-12-310001564590-19-006879EDGAR—
2018-03-192017-12-310001564590-18-006216EDGAR—
2017-03-082016-12-310001564590-17-003722EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-072025-09-300001193125-25-272383EDGAR31K words
2025-08-112025-06-300000950170-25-106644EDGAR—
2025-05-092025-03-310000950170-25-068089EDGAR—
2024-11-132024-09-300000950170-24-126306EDGAR—
2024-08-132024-06-300000950170-24-096159EDGAR—
2024-05-132024-03-310000950170-24-058642EDGAR—
2023-10-262023-09-300000950170-23-055695EDGAR—
2023-08-142023-06-300000950170-23-042218EDGAR—
2023-05-152023-03-310001564590-23-007276EDGAR—
2022-11-142022-09-300001564590-22-037555EDGAR—
2022-08-152022-06-300001564590-22-029487EDGAR—
2022-05-092022-03-310001564590-22-018775EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-230001140361-26-010654EDGAR1K words
2026-03-120001140361-26-009115EDGAR—
2026-03-120001193125-26-102700EDGAR—
2026-03-020001140361-26-007249EDGAR—
2026-01-050001140361-26-000253EDGAR—
2025-11-070001193125-25-270524EDGAR—
2025-09-100001140361-25-034506EDGAR—
2025-08-220001140361-25-032295EDGAR—
2025-08-110000950170-25-106525EDGAR—
2025-06-060001140361-25-021612EDGAR—

317 total filings indexed. 285 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001124105
TickerGYRE
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: ec1236019d3846151b3fa42181f3683ef685fc3e5c6e4dc3b472be8fda481a11
parent: 34262e5e90c9998f4322de454fb93fd0eb8de0258bbc7d79ad8e6ca105cc745f
content hash: 93e17e22c792a48b0cf4ff461b2c47bc5cd563949cb5a96c33e8edf5bd7a96f8
signed: 2026-04-13T04:45:26.148Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf